What failure? Catabasis shares soar after execs tout open-label data, PhIII plans
Before reviewing Catabasis’ second attempt at making a good first impression with its Phase II study of the Duchenne muscular dystrophy drug edasalonexent (CAT-1004), it’s important to remember what happened the first time around.
It flopped — badly — at helping patients, as researchers reported in early February. The drug failed to register a significant biomarker effect on muscle inflammation, looking very much like the placebo. And its stock $CATB was shredded.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
